# Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial

> **NCT05605587** · NA · TERMINATED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 3 (actual)

## Conditions studied

- MEN1 Gene Mutation

## Interventions

- **DRUG:** Leflunomide 20 mg

## Key facts

- **NCT ID:** NCT05605587
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-02
- **Primary completion:** 2026-01-13
- **Final completion:** 2026-01-13
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was prematurely terminated due to significant difficulties in recruiting participants, arising from the extremely rare nature of the targeted gene mutation.
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605587, "Leflunomide Treatment for MEN1 Patients - the LUMEN1 Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05605587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*